Zimbabwe has declined a major American health deal worth 367 million US dollars (272 million pounds) spanning five years due to Washington's demand for confidential information.
The decision was revealed after a internal memorandum from December was disclosed, indicating that President Emmerson Mnangagwa deemed the arrangement was "skewed".
A government spokesperson has since clarified that the US was demanding access to genetic material for research and profit but was unwilling to guarantee the benefits from any future medical innovations.
"We must now begin the challenging and unfortunate task of scaling back our health assistance in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the US had furnished over $1.9bn as health assistance to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has called for more negotiations to secure a deal suitable to both sides so the country's critical HIV treatment initiative can proceed.
Wider Context
This rejection follows a similar case in Kenya, where a court halted a similar deal with the US after concerns were raised about the security of citizens' health data.
Since resuming the presidency recently, US President Donald Trump has slashed foreign aid and shut down the US Agency for International Development (USAID).
The agency had managed aid for the American government, but Trump argued its spending was "inefficient" and his administration was seeking direct bilateral deals to boost transparency and responsibility.
Based on reports, Sixteen African countries have to date agreed to similar agreements, constituting more than $18.3bn of fresh investment.
Specifics of the Declined Deal
The funds for Zimbabwe would have funded "tackling HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this cooperation would have delivered immense benefits for Zimbabwean communities, especially the 1.2 million currently on antiretroviral therapy through US-supported programmes," the Ambassador added.
However, government spokesperson Nick Mangwana argued the arrangement was "unfair".
"The proposal required Zimbabwe to share its biological resources and data for a long time, with no equivalent guarantee of access to any medical innovations – like vaccines, diagnostics, or treatments – that could result from that shared data," Mangwana explained.
"Effectively, our nation would supply the raw materials for medical research with no assurance that the resulting innovations would be available to our citizens if a new pandemic emerge."
National Interest and International Frameworks
Mangwana further noted that the US's withdrawal from the World Health Organization (WHO) and its push of bilateral deals were undermining frameworks already established through the international organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing scheme designed to manage potential global health emergencies.
"This system is intended to ensure that when a nation contributes its information, the benefits – including medicines and cures – are distributed fairly, not monopolised exclusively by those with the resources to develop them."
These objections regarding the US deal "must not be interpreted as anti-American sentiment," Mangwana stressed.
"We are open to continued discussions with our American counterparts on how future co-operation could be structured in a way that respects the sovereignty and dignity of both nations."
Health Experts Reaction
Medical experts expressed it recognised the government's concerns, but suggested that talks need to persist since much of the country's Aids initiatives were funded by international support.
"In cases where specific concerns exist, including those involving information security or implementation frameworks, these can often be resolved through technical clarification and negotiated safeguards," it said.
The halted deal emphasises the ongoing tensions between receiving vital international aid and protecting a country's data in an ever more data-driven world.